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Abstract
Introduction
Resistance to β-lactam drugs, such as penicillins and 
cephalosporins, has become a worldwide health problem. The 
World Health Organization has listed multi-drug resistant 
Acinetobacter baumannii as requiring “top priority for new 
antibiotic development.” 3 Such antibiotic resistance derives 
primarily from β-lactamases, including Acinetobacter-derived 
cephalosporinase (ADC), which bind and destroy antibiotics. A 
recent study of clinical Acinetobacter baumannii infections 
identified the most prevalent ADC β-lactamases conveying 
antibiotic resistance. This research study seeks to determine the 
structure and function of two clinical ADC variants: ADC-30 and 
ADC-162. By using X-ray crystallography and enzyme kinetics, we 
aim to relate the small changes in structure to their enhanced 
ability to turn over antibiotics. Characterizing the structure and 
function of clinical ADC variants will be critical to developing 
molecules that could inhibit ADCs, thereby restoring antibiotic 
effectiveness. 
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§ β-lactam antibiotics bind and inhibit transpeptidase, an 
enzyme that maintains cell wall integrity.
§ Transpeptidase inhibition interrupts peptidoglycan cross-
linking, thus destabilizing the cell wall and resulting in 
eventual bacterial cell lysis.
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§ β-lactamases confer resistance to 
β-lactam antibiotics by 
hydrolyzing the key amide 
functional group.
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Penicillin with its beta lactam 
ring shown in red
• As antibiotic resistance is causing 
decreased effective drug lifetimes, 
the investment financial returns 
are also decreased.  Therefore, 
novel ways to fight bacterial 
infections are vital.
• One method is through a β -
lactam inhibitor that binds to β-
lactamases to counteract 
resistance
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• Very small changes in the protein sequences of specific ADCs have 
enabled these enzymes to contribute to a broad spectrum of 
resistance to Acinetobacter baumannii.
• Characterization of these ADC variant proteins is an important step 
in determining how these small structural changes can be 
advantageous to Acinetobacter baumannii in resisting a broader 
range of antibiotics.
• Characterizing clinically relevant ADC variants is vital to developing 
effective inhibitors against these enzymes.
Expression and Purification of ADC-162
Steady State Kinetics
0 5 0 1 0 0 1 5 0
0 .0
0 .2
0 .4
0 .6
A D C -1 6 2
[N C F ] , in µ M
v
o
 i
n
 [
p
ro
d
u
c
t]
/s
 (
µ
M
/s
)
Vmax
Km
0.6071
27.52
Km = 27.52 μM
kcat = 303 s-1
0 2 4 6 8 1 0 1 2 1 4 1 6
0 .0
0 .1
0 .2
0 .3
0 .4
0 .5
A D C -1 6 2
[M B 0 7 6 ], in µ M
v
o
 i
n
 [
p
ro
d
u
c
t]
/s
 (
µ
M
/s
)
Ki = 127.7 nM
The Process:  From bacteria to b-lactamase/inhibitor 
structure and function
“Holy grail”:
Novel In ibitor
Design 
ADC-7 subcloned into E. coli
Hangi g drop 
vapor diffusion
(crystallization)
Argonne National Labs
Enzyme kinetics provides 
information on how tightly 
each inhibitor binds to ADC-7
X-ray crystallography 
provides a picture of how 
each inhibitor specifically 
binds to ADC-7
ADC-7 purification
• A plasmid (pET28a) containing an 
Acinetobacter baumanii ADC gene was 
transformed into a non-pathenogenic
E.coli strain.
• From these colonies, protein 
expression was tested in induced and 
non-induced conditions in LB-
kanamycin.
• After confirming successful expression 
of ADC enzymes, larger growths (1 L) 
were done, and the the cell pellets was 
stored at -80 oC.
• Purified ADC-162 was crystallized via hanging 
drop vapor diffusion in (0.1 M Succinate/ 
Phosphate/Glycine, pH 5.0).
• Crystals were grown at varying concentrations 
(3-4 mg/mL) at room temperature
• Some crystals were soaked with an antibiotic  or 
inhibitor molecule
• Crystals were frozen in liquid N2 and transported 
to the Advanced Photon Source at Argonne
National Labs
• A high intensity X-ray beam focused on the crystal allowed for 
the collection of diffraction data through a 180o rotation.
• The diffraction patterns generated can be used to develop an 
electron density map of the protein.
• From the electron density map, an atomic model (ADC protein 
structure) can be determined.
• ADC-30 apo and ADC-30 with MB076 bound
• ADC-33 apo and ADC-33 with MB076 bound
• ADC-162 apo and ADC-162 with MB076 bound
• The initial reaction rate for 
each purified ADC was 
measured from the inactivation 
of a cephalosporin antibiotic, 
nitrocefin (NCF).
• Competitive inhibition kinetics allows for the determination of Ki, 
a measurement of the binding affinity of ADC-162 to the inhibitor 
MB076.  The Ki in the nanomolar range indicates high affinity to 
the inhibitor and the ability to inhibit turnover of the substrate.
• Determine the crystal structures for the three ADC variants (ADC-25, 
ADC-30, ADC-33) with and without the inhibitor MB076.
• Investigate how the small sequence changes affect the protein 
structure and how it enables increased resistance to specific 
antibiotics.
• Determine kinetics of NCF turnover and Ki for all eight ADC variants.
• Identify ideal growing conditions for ADC-25 A200D/P220L/Ainsert
crystals.
• Identify an inhibitor that will work in combination with β-lactam 
antibiotics to counteract class C β-lactamases.
• Our research ultimately will seek to discover an inhibitor for both 
class C and D β-lactamases.
• Protein gel electrophoresis (SDS-
PAGE) confirmed protein expression. 
Expression was controlled with 
IPTG. Lane 1 shows a molecular 
weight marker with a known band 
at 37kDa. 
• After purification, gel 
electrophoresis (SDS-PAGE) 
confirmed the purified 
fractions containing ADC-162.  
A molecular weight marker is 
present in lane 9 to indicate 
that ADC-162 molecular 
weight is ~40 kDa.  
• Dialysis reduced NaCl concentration 
from the elution buffer (10 kDa
cutoff).
• Protein was concentrated using an 
Amicon centrifugal filter unit.
• UV-Vis Spectrophotometer 
measured absorbance at 280nm to 
be .75 which was used to calculate 
exact concentration of protein for 
crystal trays. 
UV -Vis spectrum results for ADC-162
• Cell pellets were 
resuspended (25 mM MOPS 
pH 6.5), sonicated, 
centrifuged, and the 
resulting cell free extract 
was loaded onto a carboxy-
methyl-cellulose column at 
4 oC.
• Kinetics for the turnover of variable concentrations of NCF by 
ADC-162 (2 nM) in 10 mM NaPO4 buffer, pH 7.4 at room 
temperature, measured at 482 nm (follows the color of the 
hydrolyzed product). 
• Competitive inhibition 
kinetics for ADC-162 (2nM) 
using 60 µM nitrocefin, 10 
mM NaPO4 buffer, pH 7.4, at 
room temperature. Inhibitor 
concentration was increased 
until nearly zero turnover of 
NCF occurred. 
• β-lactamases found in Acinetobacter baumannii’s provide 
resistance to a broad spectrum of cephalosporin antibiotics.
• Acinetobacter baumannii is classified as a “serious threat” by 
the World Health Organization, and due to it’s multi-drug 
resistance, novel ways are needed to fight these infections.
• Acinetobacter is an opportunistic pathogen, infecting mostly 
patients in hospital care and others with higher susceptibility 
such as those in burn units. 3 
• Column was washed 
with 25mM MOPS, pH 
6.5 then eluted with 
25mM MOPS, pH 6.5, 
500mM NaCl
E.coli. containing ADC-162 plasmid 
Crystal tray for ADC-25
BioRad purification system with column
Argonne National Laboratories Example of a  diffraction pattern
Successfully expressed plasmids for eight ADC clinical variants:
• ADC-25 A200D/P220L/A insert
• ADC-30
• ADC-33
• ADC-162 (ADC-30 A221E)
• ADC-56
• ADC-68
• ADC-25 (ADC-30 T317N)
• ADC-33 G223D
Four of these variants have been purified through a one-step 
CM-cellulose method resulting in 30-80mg of pure protein for 
each of the following:
• ADC-25 (A200D/P220L/A insert)
• ADC-30
• ADC-33
• ADC-162 (ADC-30 A221E)
Three of these proteins were successfully crystallized. X-ray 
crystallography performed at Argonne National Laboratory 
resulted in structures between 1.25 – 1.8 Å resolution. The 
following six structures were obtained:
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